Literature DB >> 12270696

Nogo provides a molecular marker for diagnosis of amyotrophic lateral sclerosis.

Luc Dupuis1, Jose-Luis Gonzalez de Aguilar, Franck di Scala, Frédérique Rene, Marc de Tapia, Pierre-François Pradat, Lucette Lacomblez, Danielle Seihlan, Rabinder Prinjha, Frank S Walsh, Vincent Meininger, Jean-Philippe Loeffler.   

Abstract

Amyotrophic lateral sclerosis (ALS) is a fatal neurological disorder characterized by the selective degeneration of upper and lower motor neurons. The lack of a molecular diagnostic marker is of increasing concern in view of the therapeutic strategies in development. Using an unbiased subtractive suppressive hybridization screen we have identified a clone encoding the neurite outgrowth inhibitor Nogo and shown that its isoforms display a characteristic altered expression in ALS. This was first confirmed by analyzing Nogo isoform expression in a transgenic ALS model at early asymptomatic stages where we found increased levels of Nogo-A and decreased Nogo-C and importantly, not following experimentally induced denervation. Furthermore, we confirmed these changes in both post-mortem and biopsy samples from diagnosed ALS patients but not control patients. Thus, the alteration in Nogo expression pattern, common to sporadic and familial ALS, represents a potential diagnosis tool and points strongly to Nogo having a central role in disease.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12270696     DOI: 10.1006/nbdi.2002.0522

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  41 in total

Review 1.  New Insights into the Roles of Nogo-A in CNS Biology and Diseases.

Authors:  Yun-Peng Sui; Xiao-Xi Zhang; Jun-Lin Lu; Feng Sui
Journal:  Neurochem Res       Date:  2015-08-13       Impact factor: 3.996

2.  Nogo-A marks motor neuron disease.

Authors:  Noam Y Harel; Stephen M Strittmatter
Journal:  Ann Neurol       Date:  2007-07       Impact factor: 10.422

Review 3.  Amyotrophic Lateral Sclerosis: An update for 2013 Clinical Features, Pathophysiology, Management and Therapeutic Trials.

Authors:  Paul H Gordon
Journal:  Aging Dis       Date:  2013-10-01       Impact factor: 6.745

Review 4.  Issues for clinical drug development in neurodegenerative diseases.

Authors:  Michel Dib
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 5.  Use of biomarkers in ALS drug development and clinical trials.

Authors:  Nadine Bakkar; Ashley Boehringer; Robert Bowser
Journal:  Brain Res       Date:  2014-10-24       Impact factor: 3.252

Review 6.  Mechanisms controlling neuromuscular junction stability.

Authors:  Evelyne Bloch-Gallego
Journal:  Cell Mol Life Sci       Date:  2014-10-31       Impact factor: 9.261

7.  Species-dependent neuropathology in transgenic SOD1 pigs.

Authors:  Huaqiang Yang; Guohao Wang; Haitao Sun; Runzhe Shu; Tao Liu; Chuan-En Wang; Zhaoming Liu; Yu Zhao; Bentian Zhao; Zhen Ouyang; Dongshan Yang; Jiao Huang; Yueling Zhou; Shihua Li; Xiaodan Jiang; Zhicheng Xiao; Xiao-Jiang Li; Liangxue Lai
Journal:  Cell Res       Date:  2014-02-28       Impact factor: 25.617

8.  Reticulon-4A (Nogo-A) redistributes protein disulfide isomerase to protect mice from SOD1-dependent amyotrophic lateral sclerosis.

Authors:  Yvonne S Yang; Noam Y Harel; Stephen M Strittmatter
Journal:  J Neurosci       Date:  2009-11-04       Impact factor: 6.167

9.  Tissue specificity and regulation of the N-terminal diversity of reticulon 3.

Authors:  Franck Di Scala; Luc Dupuis; Christian Gaiddon; Marc De Tapia; Natasa Jokic; Jose-Luis Gonzalez de Aguilar; Jean-Sébastien Raul; Bertrand Ludes; Jean-Philippe Loeffler
Journal:  Biochem J       Date:  2005-01-01       Impact factor: 3.857

10.  Muscle mitochondrial uncoupling dismantles neuromuscular junction and triggers distal degeneration of motor neurons.

Authors:  Luc Dupuis; Jose-Luis Gonzalez de Aguilar; Andoni Echaniz-Laguna; Judith Eschbach; Frédérique Rene; Hugues Oudart; Benoit Halter; Caroline Huze; Laurent Schaeffer; Frédéric Bouillaud; Jean-Philippe Loeffler
Journal:  PLoS One       Date:  2009-04-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.